Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 2/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.63 |
| ▸ | MPO | P05164 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | HTR2B | P41595 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30356567 | 1.00 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL27917618 | 1.00 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL18029241 | 1.00 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL458570 | 1.00 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL7480435 | 0.86 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL30084863 | 0.86 | KMT2A (0.68) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL1114867 | 0.86 | KMT2A (0.68) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL1460641 | 0.86 | KMT2A (0.68) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL18029267 | 0.86 | KMT2A (0.68) | KMT2AKDM4EMAPTMEN1LMNA | |
| SCHEMBL7480432 | 0.86 | KMT2A (0.63) | KMT2AKDM4EMAPTMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3335720-A1 | C-DI-GMP BINDING PEPTIDES | Universität Basel (CH) | 2018-06-20 | — | — | EP | claimed |
| US-20260103442-A1 | AMINATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | ENVERIC BIOSCIENCES CANADA INC (CA) | 2026-04-16 | — | — | US | disclosed |
| US-12378195-B2 | Aminated psilocybin derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-20250242053-A1 | RECOMBINANT THERAPEUTIC FMR1 CONSTRUCTS AND METHODS OF TREATING FRAGILE X SYNDROME AND RELATED DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-07-31 | — | — | US | disclosed |
| US-20250136651-A1 | RECOMBINANT OPTIMIZED MECP2 CASSETTES AND METHODS FOR TREATING RETT SYNDROME AND RELATED DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2025-05-01 | — | — | US | disclosed |
| EP-4514980-A1 | RECOMBINANT THERAPEUTIC FMR1 CONSTRUCTS AND METHODS OF TREATING FRAGILE X SYNDROME AND RELATED DISORDERS | The University Court Of The University of Edinburgh (GB) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023114816-A9 | RECOMBINANT OPTIMIZED GALC CONSTRUCTS AND METHODS FOR TREATING GALC-ASSOCIATED DISORDERS | NEUROGENE INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| CN-119301258-A | Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders | 爱丁堡大学董事会 | 2025-01-10 | — | — | CN | disclosed |
| EP-4473121-A1 | RECOMBINANT OPTIMIZED MECP2 CASSETTES AND METHODS FOR TREATING RETT SYNDROME AND RELATED DISORDERS | The University Court Of The University of Edinburgh (GB) | 2024-12-11 | — | — | EP | disclosed |
| US-20240384267-A1 | COMPOSITIONS AND METHODS FOR MULTIPLEX DECODING OF QUADRUPLET CODONS | THE BROAD INSTITUTE, INC. | 2024-11-21 | — | — | US | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-20080214439-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1961817-A1 | METHOD FOR PRODUCTION OF PROTEIN HAVING NON-NATURAL TYPE AMINO ACID INTEGRATED THEREIN | Riken (JP) | 2008-08-27 | — | — | EP | disclosed |
| US-20080200641-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080125347-A1 | AMINO ACID SUBSTITUTED MOLECULES | ALLOZYNE, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080096819-A1 | Amino acid substituted molecules | ALLOZYNE, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080044854-A1 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2007149852-A2 | MODIFIED FACTOR VIII AND FACTOR IX GENES AND VECTORS FOR GENE THERAPY | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007130453-A2 | NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES | ALLOZYNE, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007103307-A2 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096819-A1 | Amino acid substituted molecules | BCAT2, DNPEP, PTMS | KMT2A 839/4885KDM4E 2570/4885MAPT 2991/4885 |
| US-20080214439-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | KMT2A 839/4885KDM4E 2570/4885MAPT 2991/4885 |
| US-20260103442-A1 | AMINATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | HTR2C, CNR2, HTR2B | KMT2A 1298/4885KDM4E 958/4885MAPT 2675/4885 |
| US-20080200641-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | KMT2A 839/4885KDM4E 2570/4885MAPT 2991/4885 |
| US-20080044854-A1 | SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES | AARS1, TRMT1, NSUN3 | KMT2A 915/4885KDM4E 1741/4885MAPT 4331/4885 |
| US-12378195-B2 | Aminated psilocybin derivatives and methods of using | CNR2, HTR2B, HTR1B | KMT2A 1640/4885KDM4E 1669/4885MAPT 1891/4885 |
| US-20080125347-A1 | AMINO ACID SUBSTITUTED MOLECULES | BCAT2, DNPEP, PTMS | KMT2A 839/4885KDM4E 2570/4885MAPT 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.